Essex Bio-Technology Limited (1061.HK)
- Previous Close
2.320 - Open
2.300 - Bid 2.250 x --
- Ask 2.300 x --
- Day's Range
2.230 - 2.300 - 52 Week Range
1.960 - 3.800 - Volume
34,000 - Avg. Volume
117,661 - Market Cap (intraday)
1.277B - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
4.79 - EPS (TTM)
0.470 - Earnings Date Mar 18, 2024
- Forward Dividend & Yield 0.09 (3.88%)
- Ex-Dividend Date May 30, 2024
- 1y Target Est
--
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology and Surgical segments. It researches and develops therapeutic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels. In addition, the company offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and mouth wash Granules; and collagen-based artificial dermis. It has license agreements with Mitotech S.A. and Mitotech LLC for clinical trial of ophthalmic solution containing SkQ1 for dry eye disease; and Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration. The company was founded in 1990 and is headquartered in Zhuhai, China.
www.essexbio.com1,481
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 1061.HK
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1061.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1061.HK
Valuation Measures
Market Cap
1.32B
Enterprise Value
1.10B
Trailing P/E
4.95
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.81
Price/Book (mrq)
0.68
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
2.63
Financial Highlights
Profitability and Income Statement
Profit Margin
16.13%
Return on Assets (ttm)
7.93%
Return on Equity (ttm)
15.06%
Revenue (ttm)
1.71B
Net Income Avi to Common (ttm)
275.26M
Diluted EPS (ttm)
0.470
Balance Sheet and Cash Flow
Total Cash (mrq)
515.03M
Total Debt/Equity (mrq)
15.28%
Levered Free Cash Flow (ttm)
204.67M
Research Analysis: 1061.HK
Company Insights: 1061.HK
1061.HK does not have Company Insights